Phase 2 trial to assess natural killer cell therapy regimen for advanced pancreatic cancer

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.The study is expected to open this month and has been approved by the FDA, according to press release issued by the companies.The randomized, two cohort, open-label QUILT-88 trial will evaluate a treatment regimen including PD-L1 tumor-targeted natural killer cells (PD-L1 t-haNK, NantKwest), the interleukin-15 superagonist N-803 (ImmunityBio) and standard-of-care chemotherapy compared withRead More

Share on facebook
Share on twitter
Share on linkedin